A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

Source:http://linkedlifedata.com/resource/pubmed/id/19903785

Clin. Cancer Res. 2009 Nov 15 15 22 7085-91

Download in:

View as

Triples

General Info

PMID
19903785